Philadelphia, Pennsylvania--(Newsfile Corp. - January 9, 2023) - It is alleged that Twist Bioscience and certain of its officers overstated the commercial viability of the company's synthetic DNA manufacturing technology while engaging in accounting fraud and using unrealistic pricing to artificially inflate Twist Bioscience's true financial condition and prospects.
Twist shareholders who have held company stock since before December 13, 2019, can seek corporate reforms, the return of funds spent defending litigation back to the company, and a court approved incentive award at no cost to them whatsoever.
If you would like to learn more about this matter, visit https://grabarlaw.com/the-latest/twist-bioscience-shareholder-investigation/, contact us at jgrabar@grabarlaw.com, or call 267-507-6085.
Attorney Advertising Disclaimer
Contact:
Joshua H. Grabar, Esq.
Grabar Law Office
One Liberty Place
1650 Market Street, Suite 3600
Philadelphia, PA 19103
Tel: 267-507-6085
Email: jgrabar@grabarlaw.com
To view the source version of this press release, please visit https://www.newsfilecorp.com/release/150712
Source: Grabar Law Office